International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 151 KB, PDF-dokument
Background: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. Key Messages: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Dermatology |
| Vol/bind | 238 |
| Sider (fra-til) | 430–437 |
| Antal sider | 8 |
| ISSN | 1018-8665 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
Folawiyo Babalola, Lesley Grilli, John Latella, Alison H. Kohn, Kendall Marcus and Lourdes M. Perez-Chada have no conflicts of interest to disclose. Dr. Alavi has served as a consultant for UCB, Janssen, Novartis, Abbvie, InflaRx. In addition, Dr. Alavi is a Section Editor of Dermatology. Dr. Armstrong has served as a research investigator and/or scientific advisor to AbbVie, ASLAN, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and Modmed. Dr. Garg is an advisor for AbbVie, Anaptys Bio, Boehringer Ingelheim, Bristol Myers Squibb, InflaRx, Incyte, Janssen, Novartis, Pfizer, UCB, and Viela Biosciences, and receives honoraria. Dr. Garg also receives research grants from AbbVie and the National Psoriasis Foundation. In addition, Dr. Garg is a Section Editor of Dermatology. Dr. Gottlieb has received honoraria as an advisory board member and consultant for Anaptyps Bio, Avotres Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb Co., Janssen, LEO Pharma, Eli Lilly, Novartis, Sun Pharmaceutical Industries Inc., UCB, and Xbiotech (only stock options), and has received research/educational grants from Boehringer Ingelheim, Janssen, Novartis, UCB, Xbiotech, and Sun Pharma (all paid to Mount Sinai School of Medicine). Dr. Jemec reports grants and personal fees from Abbvie, personal fees from Coloplast, personal fees from Chemocentryx, personal fees from LEO pharma, grants from LEO Foundation, grants from Afyx, personal fees from Incyte, grants and personal fees from InflaRx, grants from Janssen-Cilag, grants and personal fees from Novartis, grants and personal fees from UCB, grants from CSL Behring, grants from Regeneron, grants from Sanofi, personal fees from Kymera, and personal fees from VielaBio, outside the submitted work. In addition, Dr. Jemec is Editor-in-Chief of Dermatology. Dr. Merola is a consultant and/or investigator for Abbvie, Amgen, Bayer, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi-Regeneron, Biogen, Pfizer, BMS, and LEO Pharma. He may receive consulting fees, honoraria, and grant support. Dr. Ortega has served on the advisory board with honoraria at Janssen Inc. and Bristol Mayer Squibb, and has served as a consultant for Consultant Guidepoint Inc. Dr. Siegel has served as a consultant for Logical Images, MedX Health, Strata Skin Sciences, UCB, SciBASE, Pulse Biosciences, Sol-Gel Technologies, Verrica Pharmaceuticals, and Seapire Skincare. Dr. Siegel has also served on the advisory board of Tetros Group, Sun Pharmaceutical Industries Ltd, SkinVision, Biofrontera AG, Kamedis Ltd, Greenway Therapeutix, Palmm, Modernizing Medicine, and DermTech International. Dr. Strand reports consulting fees from AbbVie, Amgen, Arena, AstraZeneca, BMS, Boehringer Ingelheim, Celltrion, CORRONA, Crescendo/Myriad, Equillium, Genentech/Roche, GSK, Horizon, Inmedix, Janssen, Eli Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Samsung, Sandoz, Sanofi, TwoXAR, and UCB, outside the submitted work. Dr. Tan is an advisor, consultant, investigator, and/or speaker and received grants and honoraria from Almirall, Bausch, Botanix, Boots Walgreens, Cipher, Galderma, Novartis, Sol-Gel, Sun, and Vichy.
Publisher Copyright:
© 2021 The Author(s).
ID: 305409891